Antibodies News and Research RSS Feed - Antibodies News and Research

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research. [More]
University of Oslo researchers find the cause of coeliac disease

University of Oslo researchers find the cause of coeliac disease

Professor Ludvig M. Sollid and his colleagues at the University of Oslo have found the cause of coeliac disease. To do so required really going into depth, right down to molecular level. [More]
NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury or in individuals with impaired clotting due to an inherited condition or as a result of certain medications or chemotherapy. [More]
CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, announced today that, as part of its global manufacturing capacity expansion strategy, it has completed the expansion of its North American manufacturing facility in Bothell, Washington with the addition of a single-use Bioreactor 6Pack™ facility. [More]
Two antibodies show early promise in preventing and treating MERS

Two antibodies show early promise in preventing and treating MERS

As the South Korean epidemic of Middle East Respiratory Syndrome (MERS) continues unabated, researchers have raced to find treatments for the deadly virus, which has killed more than 400 people since it was first discovered three years ago in Saudi Arabia. [More]
TSRI-led study identifies new immune molecules that protect against Marburg virus

TSRI-led study identifies new immune molecules that protect against Marburg virus

A new study led by scientists at The Scripps Research Institute identifies new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The research provides ingredients needed to develop treatments for future Marburg outbreaks. [More]
Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia. [More]
Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. [More]
New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions. [More]
Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
UC Santa Barbara professor develops novel therapeutic strategy for PKD

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon. [More]

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. [More]
UAlberta partnership could transform cancer treatment, improve patient outcomes

UAlberta partnership could transform cancer treatment, improve patient outcomes

A multimillion dollar research partnership announced today at the University of Alberta is giving a "dream team" of researchers the opportunity to potentially transform cancer treatment and better patient outcomes. [More]
Novo Nordisk presents new data detailing the impact of hemophilia on patients, caregivers

Novo Nordisk presents new data detailing the impact of hemophilia on patients, caregivers

Today, Novo Nordisk presented new data detailing the impact hemophilia has on both caregivers and those living with the disease. [More]
Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America. [More]
New device tracks chemical messages that regulate cell growth

New device tracks chemical messages that regulate cell growth

Biomedical engineers at the University of Toronto have invented a new device that more quickly and accurately "listens in" on the chemical messages that tell our cells how to multiply. [More]
Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen. [More]
PROMISSE study: Most women with lupus can expect good pregnancy outcomes

PROMISSE study: Most women with lupus can expect good pregnancy outcomes

One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors. [More]
Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy. [More]
Advertisement
Advertisement